Cardinal Health — Oct 30, 2025 release

The company is also raising its expectations for adjusted free cash flow to $3.0 billion to $3.5 billion, from a prior range of $2.75 billion to $3.25 billion. This updated guidance reflects increased expectations at the segment level: • Pharmaceutical and Specialty Solutions segment profit growth raised to 16% to 19%, from the prior range of 11% to 13% • Other segment profit growth raised to 29% to 31%, from the prior range of 25% to 27% The company is also updating the following assumptions for the fiscal year: • Interest and other expense of ~$325 million, from a prior outlook of ~$275 million, reflecting financing costs for the Solaris Health acquisition • Diluted weighted average shares outstanding of ~238 million, from a prior range of 238 million to 240 million • Capital expenditures of $600 million to $650 million, from a prior outlook of ~$600 million Recent highlights • Cardinal Health’s Sonexus Access and Patient Support business successfully onboarded manufacturer hub programs, representing over 30 new specialty therapies launched in Q1 at Sonexus, underpinning growth expectations of over 30% in fiscal year 2026 for the company’s BioPharma Solutions business • Cardinal Health announced the location of its new flagship Pharmaceutical and Specialty Solutions forward distribution center in Indianapolis, Indiana to support the ongoing growth of the business. This 230,000 square foot facility is expected to be fully operational by Fall 2027 and will feature the latest automation and tech